Asensus Surgical Inc. (NASDAQ: ASXC) stock gained by 0.27% at last close while the ASXC stock surged by12.97% in the after-hours trading session. Asensus Surgical, Inc. is digitizing the surgeon-patient interaction to usher in a new paradigm of Performance-Guided Surgery by unlocking clinical technology to allow consistently successful results and a new surgical standard.
ASXC stock’ Financial Outcomes
ASXC stock announced its financial results for the third quarter of 2021. Given below are the highlights:
- The Company recorded revenue of $2.6 million for the third quarter of 2021, relative to $0.8 million for the third quarter of 2020. Senhance system revenue was $1.4 million in the third quarter of 2021, followed by $0.8 million in instruments and accessories and $0.4 million in services.
- Total operating expenses for the third quarter of 2021 were $16.7 million, opposed to $14.6 million for the three months ended September 30, 2020.
- The net loss in the third quarter of 2021 was $16.1 million, or $0.07 per common share, relative to $15.1 million, or $0.15 per common share, in the third quarter of 2020.
- For Q3 2021, adjusted net loss was $14.3 million, or $0.06 per common share, relative to $11.9 million, or $0.12 per common share, for the three months ended September 30, 2020.
Anthony Fernando, President, and CEO of Asensus Surgical stock commented,
They are quite pleased with their recent results. They’ve recently seen a surge in new system installations, as well as high system utilization patterns. They believe it reaffirms the market’s strong need for a cutting-edge surgical platform that adds new skills to the operating room. Likewise, surgeons who have chosen Senhance have found its unique mix of surgical intelligence and foundational laparoscopic movements to be both appealing and beneficial for themselves and their patients. They intend to build on this momentum to improve global acceptance and expand Senhance’s capabilities in order to fulfill the promise of Performance-Guided Surgery.
